Vizimpro 45 mg/1 (Dacomitinib TABLET, FILM COATED) 45 mg/1

Vizimpro 45 mg is a medication used to treat certain types of cancer. This oral tablet contains dacomitinib, a targeted therapy designed to inhibit specific cancer cell growth. Learn more about Vizimpro's uses and effects.

Strength

45 mg/1

Pack Size

30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0069-2299-30)

Manufacturer / TM Owner

Pfizer Laboratories Div Pfizer Inc

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Vizimpro 45 mg is primarily used in the treatment of non-small cell lung cancer (NSCLC). It works by targeting and inhibiting the epidermal growth factor receptor (EGFR), which can help slow the growth and spread of cancer cells. This medication is often prescribed for patients with specific genetic mutations. What is Vizimpro used for? It is used as a targeted therapy to manage certain types of lung cancer.

Side Effects

Common effects of Vizimpro 45 mg may include skin rash, diarrhea, and fatigue. Some users may also experience nausea, decreased appetite, and mouth sores. These effects can vary in severity and may require monitoring by a healthcare professional.

Precautions & Warnings

Vizimpro should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions. Patients should be aware of potential side effects and report any severe or persistent symptoms to their healthcare provider.

Avoid Interactions

Vizimpro may interact with certain medications, including those that are metabolized by the liver's CYP enzymes. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and other substances may also affect the efficacy and safety of Vizimpro.

Frequently Asked Questions

Vizimpro is used to treat non-small cell lung cancer (NSCLC) with specific genetic mutations.

Vizimpro is taken orally, typically once daily, as prescribed by a healthcare provider.

Common side effects include skin rash, diarrhea, fatigue, nausea, and mouth sores.

Vizimpro may interact with other medications, so it is important to consult a healthcare provider before combining it with other treatments.

Vizimpro should be stored at room temperature, away from moisture and heat, and kept out of reach of children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.